We advised the sales agent on the offering

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Revolution Medicines, Inc. of shares of its common stock for up to an aggregate amount of $1 billion. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”

Based in Redwood City, California, Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.

The Davis Polk corporate team included partners Alan F. Denenberg and Yasin Keshvargar and associates Dove Barbanel and Matthew Kenney. Partner David R. Bauer and associate Jordan Khorshad provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post